National Health Act 1953 - Amendment Determinations under sections 85, 85A and 88 - pharmaceutical benefits (No. PB 51 of 2008)

Overview

The National Health Act 1953 was amended by legislative instrument PB 51 of 2008 to adjust various determinations under sections 85, 85A, and 88. This instrument, which commenced on 1 June 2008, updates the Pharmaceutical Benefits Scheme (PBS) by modifying the forms, brands, and prescription details of certain pharmaceutical items. The changes, recommended by the Pharmaceutical Benefits Advisory Committee (PBAC), include the addition of new drugs and forms, alterations to existing brands, and deletions of certain pharmaceutical items that are no longer listed on the PBS. The PBAC, an independent expert body, ensures the PBS remains aligned with the latest medical evidence and cost-effectiveness considerations. The amendments aim to provide reliable, timely, and affordable access to a wide range of medicines for Australians by ensuring the PBS list is current and comprehensive.

Scope and Application

The National Health Act 1953 Amendment Determinations under sections 85, 85A, and 88, expressed to commence on 1 June 2008, amends determinations made by legislative instrument number PB 89 of 2007. These amendments pertain to the Pharmaceutical Benefits Scheme (PBS), under which the Commonwealth provides access to a wide range of medicines for all Australians. The Act applies to listed drugs and certain extemporaneously-prepared medicinal preparations, declared by the Minister by legislative instrument. It also applies to the manner of administration of a form of a listed drug, the form of a listed drug, and the brand of a pharmaceutical item. Furthermore, the Act addresses the writing of prescriptions by specified classes of persons for the supply of a pharmaceutical benefit. The instrument includes amendments to the listed drugs, forms, brands, and prescription writing rules, as recommended by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC, an independent expert body established by the Act, provides recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits. The instrument includes changes such as the addition of new listed drugs like Duloxetine and Pramipexole, alterations in brand names for various drugs, and the deletion of certain drugs and brands, reflecting the PBAC's recommendations. This legislative instrument applies nationally across Australia, extending the Commonwealth's regulatory framework over pharmaceutical benefits provided through the PBS. It does not explicitly state exclusions or thresholds but operates through subordinate instruments that determine specific aspects of the PBS. The instrument does not extend or restrict application through subordinate instruments beyond what is specified in the Act itself. The amendments set out in Schedule 1 are effective from 1 June 2008, aligning the PBS with the latest recommendations and ensuring the continued provision of timely, reliable, and affordable access to essential medicines for all Australians.

Key Provisions

The main operative sections of this legislation are subsections 85(3), 85(5), 85(6), 85A(2), and 88(1A) of the National Health Act 1953, which empower the Minister to determine various aspects of the Pharmaceutical Benefits Scheme (PBS). These provisions allow the Minister to declare the forms of listed drugs, the manner of administration, brands of pharmaceutical items, and certain aspects of prescription writing, as well as to specify which pharmaceutical benefits a dental practitioner is authorised to prescribe. These determinations are intended to ensure that the PBS provides affordable and accessible medicines to Australians, by regulating the types of drugs available, the conditions under which they can be prescribed, and the brands that are approved for use. The obligations and requirements imposed by this Act on the parties it governs are primarily administrative and compliance-based. Pharmaceutical companies must ensure that the drugs and brands they supply are declared and approved by the Minister as per the legislative instrument. Healthcare practitioners must adhere to the restrictions on prescription quantities, repetitions, and administration methods as determined by the Minister. The Minister, in turn, must make determinations based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC), which assesses the clinical effectiveness, safety, and cost-effectiveness of medicines. Additionally, the Act requires the Minister to consult with relevant stakeholders through the PBAC to ensure a broad and balanced input into the decision-making process regarding the PBS. Breaches of the obligations and requirements set out in the Act can result in various civil and criminal consequences. While the specific penalties are not detailed in the explanatory statement, it is common for breaches of legislative instruments made under the National Health Act 1953 to incur fines and potential criminal charges. For example, pharmaceutical companies that supply unapproved drugs or brands could face substantial fines, and in severe cases, criminal prosecution. Similarly, healthcare practitioners who fail to comply with prescription regulations could also face fines, professional disciplinary action, and potentially criminal charges if their actions are deemed to cause harm to patients. The exact penalties would depend on the specific nature and severity of the breach, as well as any relevant case law and statutory provisions.